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Abstract
Adult stem cells represent self-renewing, multipotent cells that are capable of
producing mature cells of another tissue through differentiation. Stem cells can
be sourced from a variety of tissues such as bone marrow, adipose tissue, and
cord blood. Bone-marrow derived mesenchymal stem cells (BM-MSC) have the
ability to differentiate, lack of ethical concerns, no teratoma potential, easily
cultured and expanded ex vivo, and are immunomodulatory via paracrine
effects. Thus, BM-MSCs have been actively used as a therapeutic agent in a
variety of clinical trials to treat diverse diseases including neurological diseases,
cardiovascular diseases, hepatic diseases, lung injury, renal failure, cancers,
wound healing and infections. However, concerns have been raised related to
high cell population heterogeneity, poorly understood homing capabilities, and a
tendency to lose biological functions in vitro with each passage. Recently,
induced pluripotent stem cells (iPSCs) have emerged as a new class of stem
cells with greater versatility. iPSC technology allows for potential treatment of
any degenerative diseases or injury due to the pluripotent potentials and
unlimited manufacturing. In this study, we established a method to generate
iPSC-derived MSCs (iMSCs). The International Society for Cellular Therapy
(ISCT) have imposed several criteria for MSCs, which include 1) plastic
adherence, 2) stable expression of CD90, CD105, and CD73 cell surface
markers, and 3) ability to differentiate into adipocytes, chondrocytes, and
osteoblasts. Our results demonstrated that iMSCs have similar property to that
of BM-MSCs by satisfying the criteria. Future directions include creating clinical
grade iMSCs which can be used for future regenerative therapies.
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Immunophenotypic analysis

• The iMSC population had greater than 95% expression of the positive

cell surface markers CD105+ and CD73+ and ~79% expression for the
positive cell surface marker CD90+. Expression of negative cell surfaces
markers was less than 1% (Figure 3).

Multilineage differentiation
Figure 2. Visualization of the experimental design. The iPSCs from human fibroblasts were converted to
mesenchymal stem cells (MSCs) through the use of induction media and supplements over ~2 weeks. To
confirm the conversion, induced MSC should display plastic adherence, have positive expression of specific
cell surface markers and be capable of differentiating into chondrocytes, adipocytes and osteocytes.

(Figure 4). Positive staining with Alcian Blue, Alizarin Red S and
BODIBY indicate chondrogenesis, osteogenesis and adipogenesis
occurred in the iMSCs, respectively.

Discussion & Future Directions
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Methods
iPSC line
The iPSC line derived from skin fibroblasts of a healthy individual (MC0192) was
used in this study. The pluripotency was validated by three germ layer
differentiation(endoderm, mesoderm and ectoderm) and pluripotency assay through
immunostaining. The mRNA expressions of stem cell markers were also confirmed
by RT-qPCR (Figure 1).
Conversion of iPSCs to iMSCs
The iPSCs were differentiated to MSCs through published protocols with minor
modification. Embryonic bodies (EBs) were formed from iPSCs by culturing in a
round bottom dish. The EBs were further differentiated into MSCs on a gelatincoated dish in a TGF-β containing medium (Figure 2).

Figure 3. Flow cytometry data for induced mesenchymal stem cells. iMSCs at passage 3 were stained with
antibodies specific to cell surfaces markers CD105+, CD90+ and CD73+ and a cocktail of negative control
markers. The iMSC population was over 95% for the cell surface markers CD105+ and CD73+ and ~79% for
CD90+ when analyzed by FACS.

Immunophenotypic analysis for iMSCs
The iMSCs were verified by flow cytometry for cell surface marker expression with
BM-MSC used as a positive control. Briefly, cells were expanded to passage 3
then stained with antibodies for the MSC positive cell surface markers CD105,
CD90 and CD73. Expression of the cell surface markers was verified using an
Attune NxT flow cytometer.
Multilineage differentiation of iMSCs
The iMSCs were differentiated into chondrocytes, adipocytes and osteocytes using
commercially available medium. For osteogenesis and adipogenesis, cells were
grown for 12-14 days in specific differentiation medium and then fixed in 4%
paraformaldehyde. Adipocyte differentiation was confirmed using BODIPY
493/503, a fluorescent stain that indicates the presence of lipids. Osteocytes were
confirmed using Alizarin Red S, a stain that detects extracellular calcium deposits.
For chondrocyte differentiation, cells were grown for 21 days under specific
differentiation medium and then fixed with 4% paraformaldehyde. Cells were then
stained with Alcian Blue, a stain that detects cartilage extracellular matrix.

• Successful multilineage differentiation of the iMSCs was observed
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In this study, we have established a method to generate mesenchymal
stem cells (MSCs) from induced pluripotent stem cells (iPSCs). We have
demonstrated that our induced MSCs (iMSCs) meet the criteria set by the
International Society of Cellular Therapy (ISCT). First, plastic adherence
was evident during the culturing of the iMSCs Second, the majority of the
iMSC population expressed the positive cell surface markers CD105+,
CD90+ and CD73+ while showing less than 1% of the negative cell surface
markers providing evidence that the iPSC cells have been differentiated
into MSC. Last, multilineage differentiation of the iMSCs was confirmed
through fluorescent and immunohistological assays after 14-21 days in
appropriate culture medium. Experiments are currently planned to test the
effectiveness of the iMSCs in T-cell proliferation. We also plan to conduct
animal models to investigate the therapeutic effects of iMSCs on sepsis
and radiation induced brain injury.
Our ultimate goal is to
generate iMSCs from
GMP-grade iPSCs, and
develop new regenerative
medicine to treat diverse
diseases including
neurological diseases,
cardiovascular diseases,
hepatic diseases, lung
injury, renal failure,
cancers, wound healing
and infections.
Stem Cells 2017;35:316–324

C

References
•

Figure 1. Characterization of human iPSC line (MC0192). (A) In vitro differentiation of the control iPSC line into all
three primary germ layers. Cells were immunostained for SOX17 (endoderm), Brachyury (mesoderm), Nestin (ectoderm),
and DAPI following fixation. Scale bar: 100 μm. Magnification: 20X. (B) Immunostaining of pluripotency markers (TRA-160 and Nanog), and DAPI (blue) Scale bar: 100μm. Magnification: 20X. (C) qRT-PCR measurements of mRNA levels of
the reprogramming factors in a commercial iPSC and a control iPSC line (MC0192), which was quantified in relation to
the skin fibroblast line.
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Figure 4. Representative images of the differentiated induced mesenchymal stem cells. (A)
Chondrogenesis staining after 21 days by Alcian Blue. (B) Osteogenesis staining after 14 days by Alizarin Red
S. (C) Adipogenesis immunostaining after 14 days with BODIPY and DAPI.
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